Today (17th January) saw an important milestone in the ICORG 11-10 / TH vs THL study with the first patient from France being enrolled.
ICORG 11-10 is a Phase III randomised study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab, and Lapatinib) in first-line treatment of HER2 postive metastatic breast cancer.
Planned study recruitment is 600 patients and the study will involve 12 countries (including Ireland).
For further details about the study, click here
Congratulations to all the team involved in this achievement and a special thanks to Dr. Romieu, Dr. Durigova, Christine and Clémence.